These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36498671)
1. Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate. Imamura T; Narang N; Kinugawa K J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498671 [TBL] [Abstract][Full Text] [Related]
2. Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure. Imamura T; Narang N; Kinugawa K J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142977 [TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia. Imamura T; Oshima A; Narang N; Kinugawa K J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884224 [TBL] [Abstract][Full Text] [Related]
4. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK; Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051 [TBL] [Abstract][Full Text] [Related]
5. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate. Oshima A; Imamura T; Narang N; Kinugawa K Clin Cardiol; 2021 Sep; 44(9):1272-1275. PubMed ID: 34263946 [TBL] [Abstract][Full Text] [Related]
6. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis. Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923 [TBL] [Abstract][Full Text] [Related]
7. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study. Dwyer JP; Agiro A; Desai P; Oluwatosin Y Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716 [TBL] [Abstract][Full Text] [Related]
8. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients. Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862 [TBL] [Abstract][Full Text] [Related]
9. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE). Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis. Khandelwal P; Shah S; McAlister L; Cleghorn S; King L; Shroff R Pediatr Nephrol; 2024 Apr; 39(4):1213-1219. PubMed ID: 37857905 [TBL] [Abstract][Full Text] [Related]
11. Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia. Imamura T; Fujioka H; Narang N; Kinugawa K J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614883 [TBL] [Abstract][Full Text] [Related]
12. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study. Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia. Takkar C; Nassar T; Qunibi W Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634 [TBL] [Abstract][Full Text] [Related]
14. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia. Yoo N; Song YB; Dubinsky I; Altshuler J Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028 [TBL] [Abstract][Full Text] [Related]
15. A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit. Qu X; Hua Y; Khan BA Cureus; 2023 Sep; 15(9):e45058. PubMed ID: 37829953 [TBL] [Abstract][Full Text] [Related]
17. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia. Cases A; Gorriz JL Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481 [TBL] [Abstract][Full Text] [Related]
18. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study. Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057 [TBL] [Abstract][Full Text] [Related]
19. Financial Implication of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia. Imamura T; Narang N; Kinugawa K Int Heart J; 2023 Nov; 64(6):1065-1070. PubMed ID: 37967978 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia. Rydell A; Thackrey C; Molki M; Mullins BP Ann Pharmacother; 2024 Aug; 58(8):790-795. PubMed ID: 37953506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]